Data Insights

Foscenvivint by Eisai for Anaplastic Thyroid Cancer: Likelihood of Approval

Foscenvivint is under clinical development by Eisai and currently in Phase I for Anaplastic Thyroid Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Anaplastic Thyroid Cancer

Data Insights

Foscenvivint by Eisai for Hepatocellular Carcinoma: Likelihood of Approval

Foscenvivint is under clinical development by Eisai and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Hepatocellular Carcinoma

Data Insights

Foscenvivint by Eisai for Endometrial Cancer: Likelihood of Approval

Foscenvivint is under clinical development by Eisai and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Endometrial Cancer

Data Insights

Foscenvivint by Eisai for Head And Neck Cancer: Likelihood of Approval

Foscenvivint is under clinical development by Eisai and currently in Phase I for Head And Neck Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Head And Neck Cancer

Data Insights

Foscenvivint by Eisai for Pancreatic Cancer: Likelihood of Approval

Foscenvivint is under clinical development by Eisai and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Pancreatic Cancer

Data Insights

Foscenvivint by Eisai for Colorectal Cancer: Likelihood of Approval

Foscenvivint is under clinical development by Eisai and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Colorectal Cancer

Data Insights

Foscenvivint by Eisai for Melanoma: Likelihood of Approval

Foscenvivint is under clinical development by Eisai and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Melanoma

Data Insights

Foscenvivint by Eisai for Ovarian Cancer: Likelihood of Approval

Foscenvivint is under clinical development by Eisai and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Ovarian Cancer

Data Insights

Foscenvivint by Eisai for Prostate Cancer: Likelihood of Approval

Foscenvivint is under clinical development by Eisai and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Prostate Cancer

Data Insights

Foscenvivint by Eisai for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval

Foscenvivint is under clinical development by Eisai and currently in Phase I for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Foscenvivint in Adrenocortical Carcinoma (Adrenal Cortex Cancer)